Switching from innovator to biosimilar (subsequent entry) infliximab an updated review of the clinical effectiveness, cost-effectiveness, and guidelines
The potential cost savings of switching to biosimilars without compromising on clinical effectiveness or safety makes investigation into the interchangeability of these drugs informative. Biosimilar drugs can potentially result in price discounts of 20% to 70%, while biosimilars were to estimated sa...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 18 January 2017
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The potential cost savings of switching to biosimilars without compromising on clinical effectiveness or safety makes investigation into the interchangeability of these drugs informative. Biosimilar drugs can potentially result in price discounts of 20% to 70%, while biosimilars were to estimated save 4.2 billion in direct spending on biologic drugs in the US market from 2014 to 2024. In 2015, CADTH reviewed the clinical and cost effectiveness of infliximab biosimilars, but found only five reports, none of which were primary studies on comparability. The lack of evidence at the time prevented conclusions on the efficacy, safety and cost-effectiveness of switching from originator to biosimilar infliximab. Several agencies such as the Food and Drug Administration (FDA) and Health Canada have now recommended biosimilar infliximab for all the indications of originator infliximab by extrapolation, and a stronger evidence base comparing the biologics has been formed since CADTH's last review. Due to the sustained healthcare policy interest in the potential of infliximab biosimilars, and new research, this review updates the 2015 CADTH report on the clinical and cost-effectiveness of infliximab biosimilars for the treatment of RA, AS, CD, UC, PA and PP. Anti-tumour necrosis factor alphas (anti-TNFs) such as infliximab (e.g., Remicade©) are biologics that are proven effective against autoimmune inflammatory diseases. Biologics are large, protein-based agents used to block inflammation for a variety of serious diseases. Infliximab can be used for a variety of chronic inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD), psoriatic arthritis (PA), and plaque psoriasis (PP). More recently, subsequent entry biosimilar drugs for infliximab have been introduced to the market due to the patent expiry of the originator (or innovator) drug. Biosimilar drugs are therapeutically and biologically similar to originators, appearing in general when exclusivity rights are lost. 'Biosimilar infliximab' is used interchangeably with subsequent entry infliximab in this review. |
|---|---|
| Item Description: | Replacement of Switching from innovator to biosimilar (subsequent entry) Infliximab. 26 February 2015. - "CADTH rapid response service"--PDF running title |
| Physical Description: | 1 PDF file (30 pages) illustration |